Zimmer Holdings currently has exposure of 75 percent for hip and knee orthopedic device markets, and the company is looking to grow., according to the Wall Street Transcript. The company has been improving manufacturing processes and fixed costs over four years and could expect to see 8 to 10 percent free cash flow yield, according to the report.
Zimmer has also been investing in emerging markets, such as China and India.
More Articles on Devices:
American Spine Expands to Gettysburg
Miami Project to Cure Paralysis Successfully Transplants Human Cells for Spinal Cord Injury
Outlook for Spinal Non-Fusion Technology Trends: Q&A with Joe Ross of LDR
Zimmer has also been investing in emerging markets, such as China and India.
More Articles on Devices:
American Spine Expands to Gettysburg
Miami Project to Cure Paralysis Successfully Transplants Human Cells for Spinal Cord Injury
Outlook for Spinal Non-Fusion Technology Trends: Q&A with Joe Ross of LDR